دورية أكاديمية
أعرض في EDS

MORBIDITY AND SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN GASTRIC CANCER: A STUDY USING THE BECKER'S CLASSIFICATION AND REGRESSION.

التفاصيل البيبلوغرافية
العنوان: MORBIDITY AND SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN GASTRIC CANCER: A STUDY USING THE BECKER'S CLASSIFICATION AND REGRESSION.
المؤلفون: Machado MCA; Universidade do Porto, Faculty of Medicine - Porto, Portugal., Barbosa JPCVL; São João University Hospital, Department of Stomatology - Porto, Portugal., Oliveira FF; Universidade do Porto, Faculty of Medicine - Porto, Portugal., Barbosa JAL; Universidade do Porto, Faculty of Medicine, Department of Surgery and Physiology - Porto, Portugal.; São João University Hospital, Department of General Surgery - Porto, Portugal.
المصدر: Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery [Arq Bras Cir Dig] 2023 Jan 09; Vol. 35, pp. e1704. Date of Electronic Publication: 2023 Jan 09 (Print Publication: 2023).
نوع المنشور: Observational Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Colégio Brasileiro de Cirurgia Digestiva Country of Publication: Brazil NLM ID: 9100283 Publication Model: eCollection Cited Medium: Internet ISSN: 2317-6326 (Electronic) Linking ISSN: 01026720 NLM ISO Abbreviation: Arq Bras Cir Dig Subsets: MEDLINE
أسماء مطبوعة: Publication: São Paulo, Brasil : Colégio Brasileiro de Cirurgia Digestiva
Original Publication: São Paulo, Brasil : Disciplina de Cirurgia do Aparelho Digestivo do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo,
مواضيع طبية MeSH: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/surgery , Stomach Neoplasms*/pathology, Humans ; Retrospective Studies ; Prognosis ; Neoplasm Staging ; Gastrectomy ; Lymph Node Excision ; Postoperative Complications/epidemiology
مستخلص: Background: Gastric cancer is an aggressive neoplasm with a poor prognosis. The multimodal approach with perioperative chemotherapy is currently the recommended treatment for patients with locally advanced gastric cancer. This treatment induces a histopathological response expressed either through the degree of regression of the primary tumor or of the lymph nodes or through yTNM staging. Despite its advantages, there are still doubts regarding the effects of chemotherapy on postoperative morbidity and mortality.
Aims: This study aims to evaluate the impact of perioperative chemotherapy and its effect on anatomopathological results and postoperative morbidity and on patient survival.
Methods: This is an observational retrospective study on 134 patients with advanced gastric cancer who underwent perioperative chemotherapy and curative radical surgery. The degree of histological regression of the primary tumor was evaluated according to Becker's criteria; the proportion of regressed lymph nodes was determined, and postoperative complications were evaluated according to the Clavien-Dindo classification. Survival times were compared between the groups using Kaplan-Meier curves and the Mantel-Cox log-rank test.
Results: In all, 22.3% of the patients were classified as good responders and 75.9% as poor responders. This variable was not correlated with operative morbidity (p=1.68); 64.2% of patients had invaded lymph nodes and 46.3% had regressed lymph nodes; and 49.4% had no lymphatic invasion and 61.9% had no signs of venous invasion. Postoperative complications occurred in 30.6% of the patients. The group of good responders had an average survival of 56.0 months and the group of poor responders had 34.0 months (p=0.17).
Conclusion: Perioperative chemotherapy induces regression in both the primary tumor and lymph nodes. The results of the operative morbidity were similar to those described in the literature. However, although the group of good responders showed better survival, this value was not significant. Therefore, further studies are needed to evaluate the importance of the degree of lymph node regression and its impact on the survival of these patients.
References: Medicine (Baltimore). 2018 Oct;97(43):e12932. (PMID: 30412102)
Br J Cancer. 2014 Apr 2;110(7):1712-20. (PMID: 24569472)
Pathol Res Pract. 2020 Sep;216(9):153073. (PMID: 32825946)
Cancer Res Treat. 2021 Jan;53(1):112-122. (PMID: 32777876)
Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308)
Surg Today. 2021 May;51(5):821-828. (PMID: 33170366)
J Surg Oncol. 2020 Apr;121(5):795-803. (PMID: 31773740)
APMIS. 2017 Feb;125(2):79-84. (PMID: 28044374)
World J Gastrointest Oncol. 2019 Jan 15;11(1):48-58. (PMID: 30984350)
J Gastrointest Surg. 2020 Jun;24(6):1278-1289. (PMID: 31140064)
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. (PMID: 27664260)
J Surg Oncol. 2020 Apr;121(5):833-839. (PMID: 31943232)
Ann Surg Oncol. 2021 Mar;28(3):1428-1436. (PMID: 32862371)
Ann Surg. 2011 May;253(5):934-9. (PMID: 21490451)
J Surg Oncol. 2021 Mar;123(4):923-931. (PMID: 33497471)
Eur J Surg Oncol. 2018 May;44(5):613-619. (PMID: 29503129)
BMC Gastroenterol. 2017 Mar 14;17(1):41. (PMID: 28292272)
Ann Surg Oncol. 2020 Sep;27(9):3296-3304. (PMID: 32219726)
J Gastrointest Oncol. 2017 Dec;8(6):1018-1025. (PMID: 29299362)
World J Surg Oncol. 2020 Aug 24;18(1):224. (PMID: 32838799)
Br J Surg. 2014 Nov;101(12):1560-5. (PMID: 25200278)
Cancers (Basel). 2021 May 20;13(10):. (PMID: 34065596)
Chin Med J (Engl). 2021 Jun 24;134(14):1669-1680. (PMID: 34397593)
Eur J Cancer. 2020 Jan;124:67-76. (PMID: 31759294)
J Clin Oncol. 2016 Aug 10;34(23):2721-7. (PMID: 27298411)
Ann Surg Oncol. 2015 Oct;22(11):3632-9. (PMID: 25676845)
Br J Surg. 1998 Nov;85(11):1457-9. (PMID: 9823902)
Lancet Oncol. 2016 Dec;17(12):1697-1708. (PMID: 27776843)
Gastroenterol Res Pract. 2020 Jul 18;2020:3435673. (PMID: 32733550)
Arq Bras Cir Dig. 2021 May 14;34(1):e1563. (PMID: 34008707)
تواريخ الأحداث: Date Created: 20230111 Date Completed: 20230113 Latest Revision: 20230120
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9831635
DOI: 10.1590/0102-672020220002e1704
PMID: 36629685
قاعدة البيانات: MEDLINE
الوصف
تدمد:2317-6326
DOI:10.1590/0102-672020220002e1704